## CLAIMS:

1. A therapeutic or diagnostic composition, comprising an excipient or pharmaceutical additive and a compound having the following formula:

$$H_3C - R_1 - (CH_2)_2 - R_2$$

wherein  $\ensuremath{R_1}$  is selected from the group consisting of

wherein  $R_2$  is selected from the group consisting of

$$\begin{array}{c|cccc}
O & O & O \\
\hline
O & P & C & P & O \\
\hline
O & H_2 & D \\
\hline
O & Cat^{+} & O & Cat^{+}
\end{array}$$

Methylenediphosphonate,

$$\begin{array}{c|c}
O & O & O \\
\hline
O & C & P & O \\
\hline
O & Cat^{+} & O^{-}Cat^{+}
\end{array}$$

Difluoromethylenediphosphonate,

and

Monofluoromethylenediphosphonate,

and wherein Cat+ represents one or more organic or mineral cations, comprising the proton, identical or different, in

the same compound, excepting 3-methyl-3-butene-1-yl-difluoromethylenediphosphonate, and 3-methyl-3-butene-1-yl-methylenediphosphonate.

- 2. The composition according to claim 1, wherein said excipient or pharmaceutical additive is a vaccine adjuvant.
- 3. The composition according to claim 1, wherein said composition can be safely administered to a primate.
- 4 A method for selectively inhibiting  $T\gamma9\delta2$  lymphocytes, comprising:

contacting said  $T\gamma 9\delta 2$  lymphocytes with an effective amount of the composition according to claim 1.

- 5. A method for treating a patient that suffer from a pathology that activates  $T\gamma 9\delta 2$  lymphocytes, comprising:
- administering to said patient in need thereof an effective amount of the composition according to claim 1.
- 6. A method for treating a pathology leading to an activation of  $T\gamma9\delta2$  lymphocytes in a primate, comprising:

administering to said primate in need thereof an effective amount of the composition according to claim 1.

7. A method for treating parasitosis in a primate, comprising:

administering to said primate in need thereof an effective amount of the composition according to claim 1.

- 8. The method according to claim 6, wherein said parasitosis is selected from the group consisting of malaria, visceral leishmaniosis, toxoplasmosis.
- 9. A method for treating an autoimmune malady in a primate, comprising:

administering to said primate in need thereof an effective amount of the composition according to claim 1.

- 10. The method according to claim 8, wherein said malady is behoet malady.
- 11. A method for selectively inhibiting  $T\gamma 9\delta 2$  lymphocytes in an extracorporeal medium, comprising:

contacting said T $\gamma 9\delta 2$  lymphocytes in said extracorporeal medium with an effective amount of the composition according to claim 1.

12. A method for inhibiting polyclonal proliferation of Ty982 lymphocytes, comprising:

contacting said T $\gamma 9\delta 2$  lymphocytes with an effective amount of the composition according to claim 1.